Aquaporin Announces Rights Issue to Propel Water Technology Growth
Aquaporin A/S, a pioneering company in the water technology sector, has recently announced its decision to introduce a rights issue enabling current shareholders to acquire new shares. This strategic move aims to raise approximately DKK 78 million, which will be funnelled into the company's ambitious growth plans, refining its product offerings and enhancing its operational capabilities in the water filtration domain.
Established with a mission to revolutionize water purification processes through biotechnology, Aquaporin is well regarded for its innovative approach to tackling global water challenges. The rights issue, which allows existing shareholders to purchase up to 77,536,770 new shares at a subscription price of DKK 1 each, is designed to ensure the company remains adequately funded to continue its activities and achieve profitability in the medium term.
Ulrik Lund Jakobsen, the CEO of Aquaporin, emphasized the significance of the rights issue, stating that it is critical for the firm to secure the necessary capital for the coming year. With a solid operational back-end and a skilled team steering the company, Aquaporin is poised to capitalize on the funds raised from this offering to push its water purification technologies to greater heights. Over recent years, the company has garnered substantial validation from clients, indicating a solid foundation for expansion.
Niels Heering, the Chair of the Board of Directors, explained that this decision came after a rigorous strategic review, supported by feedback from shareholders at a recent extraordinary general meeting. The proceeds from the rights issue are expected to facilitate Aquaporin’s mission towards achieving profitability while enhancing their focus on Industrial Reverse Osmosis and Forward Osmosis technologies - key areas in the company's strategic framework.
Existing shareholders must act quickly as the subscription ratio is set at 103, meaning that for every existing share, shareholders will be allocated ten Pre-emptive Rights. Moreover, three of these rights will be required to subscribe for one new share at the nominal price. It is crucial for investors to consider the potential dilution of their shares, as failure to subscribe to their proportional share may result in a reduction of their stake by up to 77% should all new shares be taken.
The rights issue is planned to commence on January 7, 2026, and will run until January 20, 2026, during which the Pre-emptive Rights will be available for trading on Nasdaq Copenhagen under a temporary ISIN code. The gross proceeds from the offering are crucial as Aquaporin aims to finance its operations for the fiscal year ending December 31, 2026, and further promote the upcoming generation of its flagship Aquaporin Inside® technology (AiG2). Commercialization for AiG2 is anticipated to initiate between 2027 and 2028, representing a significant leap towards achieving long-term growth targets.
The company has stated that no minimum amount is set for the offering but anticipates substantial uncertainty should it raise significantly less than expected. Notably, Aquaporin has secured advance support in the form of pre-subscription commitments from major existing shareholders, which could cover an amount of up to DKK 20.7 million, representing about 27.9% of the planned new shares, providing a safety net for the rights issue's success.
As Aquaporin ventures into this new phase, its commitment to innovative water solutions, aligned with responsible operational practices, underscores the significant potential of biotechnology in addressing water scarcity issues. Investing in Aquaporin through this rights issue presents an opportunity for shareholders to further their stake in a company that is not only tech-driven but also responsive to the pressing global challenges of our time. Those interested are encouraged to read through the Information Document available on Aquaporin's website for comprehensive details before committing to the offering.
Established with a mission to revolutionize water purification processes through biotechnology, Aquaporin is well regarded for its innovative approach to tackling global water challenges. The rights issue, which allows existing shareholders to purchase up to 77,536,770 new shares at a subscription price of DKK 1 each, is designed to ensure the company remains adequately funded to continue its activities and achieve profitability in the medium term.
Ulrik Lund Jakobsen, the CEO of Aquaporin, emphasized the significance of the rights issue, stating that it is critical for the firm to secure the necessary capital for the coming year. With a solid operational back-end and a skilled team steering the company, Aquaporin is poised to capitalize on the funds raised from this offering to push its water purification technologies to greater heights. Over recent years, the company has garnered substantial validation from clients, indicating a solid foundation for expansion.
Niels Heering, the Chair of the Board of Directors, explained that this decision came after a rigorous strategic review, supported by feedback from shareholders at a recent extraordinary general meeting. The proceeds from the rights issue are expected to facilitate Aquaporin’s mission towards achieving profitability while enhancing their focus on Industrial Reverse Osmosis and Forward Osmosis technologies - key areas in the company's strategic framework.
Existing shareholders must act quickly as the subscription ratio is set at 103, meaning that for every existing share, shareholders will be allocated ten Pre-emptive Rights. Moreover, three of these rights will be required to subscribe for one new share at the nominal price. It is crucial for investors to consider the potential dilution of their shares, as failure to subscribe to their proportional share may result in a reduction of their stake by up to 77% should all new shares be taken.
The rights issue is planned to commence on January 7, 2026, and will run until January 20, 2026, during which the Pre-emptive Rights will be available for trading on Nasdaq Copenhagen under a temporary ISIN code. The gross proceeds from the offering are crucial as Aquaporin aims to finance its operations for the fiscal year ending December 31, 2026, and further promote the upcoming generation of its flagship Aquaporin Inside® technology (AiG2). Commercialization for AiG2 is anticipated to initiate between 2027 and 2028, representing a significant leap towards achieving long-term growth targets.
The company has stated that no minimum amount is set for the offering but anticipates substantial uncertainty should it raise significantly less than expected. Notably, Aquaporin has secured advance support in the form of pre-subscription commitments from major existing shareholders, which could cover an amount of up to DKK 20.7 million, representing about 27.9% of the planned new shares, providing a safety net for the rights issue's success.
As Aquaporin ventures into this new phase, its commitment to innovative water solutions, aligned with responsible operational practices, underscores the significant potential of biotechnology in addressing water scarcity issues. Investing in Aquaporin through this rights issue presents an opportunity for shareholders to further their stake in a company that is not only tech-driven but also responsive to the pressing global challenges of our time. Those interested are encouraged to read through the Information Document available on Aquaporin's website for comprehensive details before committing to the offering.
Topics Consumer Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.